Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. raised its position in Exact Sciences Co. (NASDAQ:EXAS) by 35.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 95,827 shares of the medical research company’s stock after acquiring an additional 24,992 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.05% of Exact Sciences worth $5,385,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EXAS. William Blair Investment Management LLC acquired a new stake in Exact Sciences in the second quarter valued at $163,896,000. Groupama Asset Managment purchased a new stake in Exact Sciences during the third quarter worth approximately $821,000. Sculptor Capital LP acquired a new position in Exact Sciences in the second quarter valued at approximately $32,819,000. Samlyn Capital LLC purchased a new position in Exact Sciences in the second quarter valued at approximately $30,426,000. Finally, Armistice Capital LLC raised its holdings in Exact Sciences by 91.6% during the second quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock worth $59,154,000 after purchasing an additional 669,438 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Trading Down 0.3 %

Shares of EXAS stock opened at $56.50 on Friday. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The business’s fifty day moving average price is $58.09 and its 200 day moving average price is $58.56. The firm has a market capitalization of $10.46 billion, a PE ratio of -48.29 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company had revenue of $708.66 million for the quarter, compared to analysts’ expectations of $716.80 million. Exact Sciences’s quarterly revenue was up 12.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Exact Sciences Co. will post -1.13 EPS for the current fiscal year.

Insider Buying and Selling

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was bought at an average price of $51.35 per share, for a total transaction of $1,001,325.00. Following the completion of the transaction, the chief executive officer now owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.36% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

EXAS has been the topic of several research analyst reports. Evercore ISI cut their price target on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. BTIG Research boosted their target price on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. The Goldman Sachs Group dropped their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Benchmark decreased their price objective on Exact Sciences from $67.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, TD Cowen lifted their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. One analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.94.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.